Evidence
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664. Online ahead of print.
ABSTRACT
BACKGROUND AND AIM: In relation to the new umbrella terminology for steatotic liver disease (SLD), we aimed to elucidate the prevalence, distribution and clinical characteristics of the SLD subgroups in the primary care setting.
APPROACH AND METHOD: We retrospectively collected data from 2,535 individuals who underwent magnetic resonance imaging elastography (MRE) and proton density fat fraction (MRI-PDFF) during health check-ups in five primary care health promotion clinics. We evaluated the presence of cardiometabolic risk factors according to predefined criteria and divided all the participants according to the new SLD classification.
RESULT AND CONCLUSION: The prevalence of SLD was 39.13% in the total cohort, and 95.77% of the SLD cases had metabolic dysfunction (one or more cardiometabolic risk factors). The prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) was 29.51%, with those of metabolic dysfunction and increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD) at 7.89% and 0.39%, respectively. According to the old criteria, the prevalence of non-alcoholic fatty liver disease (NAFLD) was 29.11%, and 95.80% of the NAFLD cases fulfilled the new criteria for MASLD. The distribution of SLD subtypes was highest for MASLD, at 75.40%, followed by MetALD at 20.06%, cryptogenic SLD at 3.33%, and ALD at 1.01%. The MetALD group had a significantly higher mean MRE than the MASLD or ALD group. Almost all the NAFLD patients met the new criteria for MASLD. The fibrosis burden of the MetALD group was higher than those of the MASLD and ALD groups.
PMID:38100294 | DOI:10.1097/HEP.0000000000000664
Add to Google Keep
Estimated reading time: 5 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
🌐 90 Days
VR Related Evidence Matrix
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE
- Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Cross-Sectional Study
- Metabolic disease and the liver: A review
- A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease
- Letter To The Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- The Global Epidemic of Metabolic Fatty Liver Disease
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Prevalence and Factors Associated with Stress, Anxiety and Depression amongst Primary Care Patients with Hepatitis B and C Infections in Nigeria
- COVID-19 in Individuals with Chronic Liver Diseases
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Cardiac remodelling in non-alcoholic fatty liver disease in the general population
- Mannose Supplementation Curbs Liver Steatosis and Fibrosis in Murine MASH by Inhibiting Fructose Metabolism
- Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn's disease
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters
- Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters
- Occult liver disease: a multinational perspective
- Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials
- Primary Hepatic Melanoma: A Diagnostic Surprise
- Burden and correlates of significant liver fibrosis among HIV-infected and uninfected adults in urban Uganda
- Review: application of the Safety Attitudes Questionnaire (SAQ) in primary care - a systematic synthesis on validity, descriptive and comparative results, and variance across organisational units
- The double roles of T cell-mediated immune response in the progression of MASLD
- Disparities in Access to a Regular Primary Care Physician Among First-Generation Migrants with Early Psychosis in Ontario, Canada
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Evaluation of Antisense Oligonucleotides Therapy Targeting Hsd17b13 in a Fibrosis Mice Model
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Associations between vascular health, brain stiffness and global cognitive function
- The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis
- Association of metabolic syndrome components and NAFLD with quality of life: Insights from a cross-sectional study
- Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
- Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Factors Associated with Delayed Care Among Women Veterans Actively Engaged in Primary Care
- Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
Evidence Blueprint
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
🌐 365 Days
VR Related Evidence Matrix
- National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype
- Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD
- A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity
- Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence severity, and long-term outlook for SLD and subclassifications
- From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need
- Quantitative ultrasound fatty liver evaluation in a pediatric population: comparison with magnetic resonance imaging of liver proton density fat fraction
- Deep Learning for Inference of Hepatic Proton-Density Fat Fraction From T1-Weighted In-Phase and Opposed-Phase MRI: Retrospective Analysis of Population-Based Trial Data
- Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis
- Which obesity index is the most useful marker for predicting hepatic steatosis in children and adolescents with obesity? A cross-sectional study using quantitative magnetic resonance imaging
- MR Elastography: Practical Questions, From the AJR Special Series on Imaging of Fibrosis
- Low Health Literacy, Lack of Knowledge, and Self-Control Hinder Healthy Lifestyles in Diverse Patients with Steatotic Liver Disease
- PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Cross-Sectional Study
- How to identify at-risk NAFLD in the primary care setting
- Evaluation of proton density fat fraction (PDFF) obtained from a vendor-neutral MRI sequence and MRQuantif software
- Co-existence of hepatic and pancreatic fibrosis in chronic pancreatitis patients including associated risk factors: a magnetic resonance elastography study
- Assessment of Specific Learning Disabilities and Intellectual Disabilities
- Metabolic disease and the liver: A review
- Ultrasound Shear Wave Attenuation Imaging for Grading Liver Steatosis in Volunteers and Patients With Non-alcoholic Fatty Liver Disease: A Pilot Study
- Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease
- Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
- Plant-based diets, genetic predisposition and risk of non-alcoholic fatty liver disease
- Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications
- A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
- The Landscape of Aberrant Alternative Splicing Events in Steatotic Liver Graft Post Transplantation via Transcriptome-Wide Analysis
- Diagnostic Performance of Noninvasive Tests for Advanced Hepatic Fibrosis in Young Age Population
- Histopathological correlations and fat replacement imaging patterns in recessive limb-girdle muscular dystrophy type 12
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- MBOAT7 in liver and extrahepatic diseases
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease
- Letter to the Editor: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Letter To The Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease
- Hepatic steatosis and NAFLD are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
- Plasma Amino Acids in NAFLD Patients with Obesity Are Associated with Steatosis and Fibrosis: Results from the MAST4HEALTH Study
- Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-alcoholic fatty liver disease patients
- Diagnostic Value of FibroTouch in Identifying Hepatic Steatosis in NAFLD with MRI-PDFF as the Reference Standard
- Shift work and evening chronotype are associated with hepatic fat fraction and non-alcoholic fatty liver disease in 282,303 UK biobank participants
- Prevalence of Subclinical Cardiovascular Disease in Patients with Non-Alcoholic-Fatty Liver Disease: Analysis of the Paracelsus 10.000 Cohort Study
- Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients